Akcea Logo
  • Akcea Connect UK
  • Akcea Therapeutics UK
    • Akcea Therapeutics US
  • About us
    • Mission and leadership
    • Careers
    • Contact us
  • News
  • Rare diseases
    • Our technology
    • Our therapeutic areas
    • Our approved medicines
  • For healthcare professionals
  • For patients & families
    • Our commitment
    • Resources
    • Patient stories

The information contained in this section of the site is intended for UK healthcare professionals only. Please confirm you are a healthcare professional to continue.

I confirm I am a UK healthcare professional

Continue
Go back

News

Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease

Published date: 02/01/2020
AKCUK-070 | September 2020

Back to news listing

Recent Posts

  • WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland
  • Akcea celebrates third global Familial Chylomicronaemia Syndrome (FCS) awareness day
  • WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England
  • Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease
  • Tegsedi®▼ (inotersen) to be made available on the NHS in Scotland for people with rare hATTR amyloidosis
  • Terms of use
  • Cookie policy
  • Privacy policy
  • Careers
  • Contact us

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ Adverse events should also be reported to Akcea Therapeutics UK Ltd:
Email: MedInfoUK@akceatx.com
Telephone: +44 (0) 330 159 0174

© 2020, all rights reserved.
AKC-056-002 | September 2020

Akcea Therapeutics UK Ltd,

Regus Building
Brooklands Business Park
Wellington Way
Weybridge
Surrey
KT13 0TT
UK

+44 (0)1932 871862
UKinfo@akceatx.com
MedInfoUK@akceatx.com